Agios Pharmaceuticals Analyst Price Targets

Wall Street analyst price targets and consensus rating for Agios Pharmaceuticals (AGIO).

Price Target Range — 13 Quarters

Analyst Consensus — 10 Analysts

7Buy

3Hold

Consensus RatingBuy# Analysts10Avg. Consensus PT$46Upside to Avg. PT+47.0%

Rating Trend — Last 9 Months

Recent Analyst Actions

See all ratings →

Date	Firm	Analyst	Action	Rating Change	Price Target
Oct 29, 2026	HC Wainwright & Co.	Douglas Tsao	Assumes	Buy	$55
Oct 7, 2026	Truist Securities	Gregory Renza	PT Cut	Buy	$39→$37
Sep 21, 2026	B of A Securities	Alec Stranahan	PT Raise	Buy	$46→$50
Aug 7, 2026	JP Morgan	Tessa Romero	PT Raise	Neutral	$31→$34
Jul 31, 2026	Citigroup	Samantha Semenkow	PT Raise	Buy	$46→$52
Jul 31, 2026	Truist Securities	Gregory Renza	PT Cut	Buy	$41→$39
Jul 30, 2026	HC Wainwright & Co.	Emily Bodnar	PT Raise	Buy	$52→$55
Jul 21, 2026	HC Wainwright & Co.	Emily Bodnar	PT Cut	Buy	$50→$52
Jul 7, 2026	RBC Capital	Luca Issi	PT Raise	Sector Perform	$28→$32
Jul 7, 2026	Truist Securities	Gregory Renza	PT Raise	Buy	$36→$41
Jul 7, 2026	B of A Securities	Alec Stranahan	PT Raise	Buy	$40→$46
Jun 15, 2026	HC Wainwright & Co.	Emily Bodnar	Maintained	Buy	$54
Jun 11, 2026	JP Morgan	Tessa Romero	PT Cut	Neutral	$36→$31
May 29, 2026	B of A Securities	Greg Harrison	PT Cut	Buy	$41→$40
Apr 30, 2026	Truist Securities	Gregory Renza	PT Cut	Buy	$39→$36
Apr 21, 2026	B of A Securities	Greg Harrison	PT Cut	Buy	$44→$41
Apr 20, 2026	HC Wainwright & Co.	Emily Bodnar	PT Cut	Buy	$65→$50
Apr 6, 2026	JP Morgan	Tessa Romero	PT Raise	Neutral	$31→$36
Apr 1, 2026	Goldman Sachs	Salveen Richter	PT Raise	Neutral	$28→$32
Mar 5, 2026	Citigroup	Samantha Semenkow	PT Raise	Buy	$38→$46

Analyst Ratings News

PRO
HC Wainwright & Co. Assumes Agios Pharmaceuticals at Buy, Announces Price Target of $55

HC Wainwright & Co. analyst Douglas Tsao assumes Agios Pharmaceuticals (NASDAQ:AGIO) with a Buy rating and announces Price Target of $55.

Benzinga Newsdesk

PRO
Truist Securities Maintains Buy on Agios Pharmaceuticals, Lowers Price Target to $37

Truist Securities analyst Gregory Renza maintains Agios Pharmaceuticals (NASDAQ:AGIO) with a Buy and lowers the price target from $39 to $37.

Benzinga Newsdesk

PRO
B of A Securities Maintains Buy on Agios Pharmaceuticals, Raises Price Target to $50

B of A Securities analyst Alec Stranahan maintains Agios Pharmaceuticals (NASDAQ:AGIO) with a Buy and raises the price target from $46 to $50.

Benzinga Newsdesk

PRO
JP Morgan Maintains Neutral on Agios Pharmaceuticals, Raises Price Target to $34

JP Morgan analyst Tessa Romero maintains Agios Pharmaceuticals (NASDAQ:AGIO) with a Neutral and raises the price target from $31 to $34.

Benzinga Newsdesk

PRO
Citigroup Maintains Buy on Agios Pharmaceuticals, Raises Price Target to $52

Citigroup analyst Samantha Semenkow maintains Agios Pharmaceuticals (NASDAQ:AGIO) with a Buy and raises the price target from $46 to $52.

Benzinga Newsdesk

PRO
Truist Securities Maintains Buy on Agios Pharmaceuticals, Lowers Price Target to $39

Truist Securities analyst Gregory Renza maintains Agios Pharmaceuticals (NASDAQ:AGIO) with a Buy and lowers the price target from $41 to $39.

Benzinga Newsdesk

Agios Pharmaceuticals Inc

Agios Pharmaceuticals Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PRO
HC Wainwright & Co. Assumes Agios Pharmaceuticals at Buy, Announces Price Target of $55

PRO
Truist Securities Maintains Buy on Agios Pharmaceuticals, Lowers Price Target to $37

PRO
B of A Securities Maintains Buy on Agios Pharmaceuticals, Raises Price Target to $50

PRO
JP Morgan Maintains Neutral on Agios Pharmaceuticals, Raises Price Target to $34

PRO
Citigroup Maintains Buy on Agios Pharmaceuticals, Raises Price Target to $52

PRO
Truist Securities Maintains Buy on Agios Pharmaceuticals, Lowers Price Target to $39

People Also Watch

People Also Watch

Agios Pharmaceuticals Inc

Agios Pharmaceuticals Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PROHC Wainwright & Co. Assumes Agios Pharmaceuticals at Buy, Announces Price Target of $55

PROTruist Securities Maintains Buy on Agios Pharmaceuticals, Lowers Price Target to $37

PROB of A Securities Maintains Buy on Agios Pharmaceuticals, Raises Price Target to $50

PROJP Morgan Maintains Neutral on Agios Pharmaceuticals, Raises Price Target to $34

PROCitigroup Maintains Buy on Agios Pharmaceuticals, Raises Price Target to $52

PROTruist Securities Maintains Buy on Agios Pharmaceuticals, Lowers Price Target to $39

People Also Watch

People Also Watch

PRO
HC Wainwright & Co. Assumes Agios Pharmaceuticals at Buy, Announces Price Target of $55

PRO
Truist Securities Maintains Buy on Agios Pharmaceuticals, Lowers Price Target to $37

PRO
B of A Securities Maintains Buy on Agios Pharmaceuticals, Raises Price Target to $50

PRO
JP Morgan Maintains Neutral on Agios Pharmaceuticals, Raises Price Target to $34

PRO
Citigroup Maintains Buy on Agios Pharmaceuticals, Raises Price Target to $52

PRO
Truist Securities Maintains Buy on Agios Pharmaceuticals, Lowers Price Target to $39